{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T16:06:33Z","timestamp":1783008393756,"version":"3.54.5"},"reference-count":73,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T00:00:00Z","timestamp":1613433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p><jats:bold>Objectives:<\/jats:bold>While opioids temporarily alleviate pain, the overshoot of balancing pain drivers may increase pain, leading to opioid induced hyperalgesia (OIH). Our goal was to find out what chronic opioid treatment does to pain tolerance as measured by the cold pressor test (CPT), an objective measure of pain tolerance, and to find an alternative effective treatment for chronic pain and FM.<\/jats:p><jats:p><jats:bold>Materials and Methods:<\/jats:bold>The setting was an academic addiction medicine service that has an embedded pain service. Patients had routine clinical care starting with an evaluation that included assessment of medical and psychiatric conditions. Participants were 55 patients with OIH and 21 patients with fibromyalgia; all had at least two CPTs. Treatment included a single dose of buprenorphine for detoxification. In this open-label case series, patients were treated with low dose naltrexone (LDN), a pure opioid receptor antagonist that, we hypothesize, treats OIH and FM by restoring endogenous opioid tone.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold>Comparing initial and last CPT times, those with OIH more than quadrupled their pain tolerance, and those with FM doubled theirs. This improved pain tolerance for OIH and FM was statistically significant (<jats:italic>p<\/jats:italic>&amp;lt; 0.0001 and<jats:italic>p<\/jats:italic>= 0.003, respectively) and had a large effect size (<jats:italic>r<\/jats:italic>= 0.82 and<jats:italic>r<\/jats:italic>= 0.63, respectively).<\/jats:p><jats:p><jats:bold>Discussion:<\/jats:bold>Results suggest that patients on chronic opioid therapy should have pain tolerance measured by CPT with detoxification and LDN provided to correct opioid induced hyperalgesia if found. FM may also be treated with LDN. The main limitation of the findings was lack of a randomized control group treated with placebo.<\/jats:p>","DOI":"10.3389\/fpsyt.2021.593842","type":"journal-article","created":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T12:35:05Z","timestamp":1613651705000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":32,"title":["The Effects of Low Dose Naltrexone on Opioid Induced Hyperalgesia and Fibromyalgia"],"prefix":"10.3389","volume":"12","author":[{"given":"Daniel","family":"Jackson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunita","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanli","family":"Zhang-James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Faraone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,2,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e1919066","DOI":"10.1001\/jamanetworkopen.2019.19066","article-title":"Association of medicaid expansion with opioid overdose mortality in the United States","volume":"3","author":"Kravitz-Wirtz","year":"2020","journal-title":"JAMA Netw Open."},{"key":"B2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.36076\/ppj.2011\/14\/145","article-title":"A comprehensive review of opioid-induced hyperalgesia","volume":"14","author":"Lee","year":"2011","journal-title":"Pain Physician."},{"key":"B3","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1097\/AJP.0000000000000814","article-title":"Attitudes towards and management of opioid-induced hyperalgesia: a survey of chronic pain practitioners","volume":"36","author":"Kum","year":"2020","journal-title":"Clin J Pain."},{"key":"B4","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.jpain.2008.03.005","article-title":"Oxycodone plus ultra-low-dose naltrexone attenuates neuropathic pain and associated \u03bc-opioid receptor\u2013gs coupling","volume":"9","author":"Largent-Milnes","year":"2008","journal-title":"J Pain."},{"key":"B5","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/AJP.0000000000000705","article-title":"Molecular biology of opioid analgesia and its clinical considerations","volume":"35","author":"Finkel","year":"2019","journal-title":"Clin J Pain."},{"key":"B6","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1097\/AJP.0b013e31816b2f43","article-title":"Opioid-induced hyperalgesia in humans","volume":"24","author":"Chu","year":"2008","journal-title":"Clin J Pain."},{"key":"B7","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1097\/00000542-200603000-00025","article-title":"Opioid-induced Hyperalgesia","volume":"104","author":"Angst","year":"2006","journal-title":"Anesthesiology."},{"key":"B8","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.1038\/sj.emboj.7600799","article-title":"Phosphorylation of EEA1 by p38 MAP kinase regulates \u03bc opioid receptor endocytosis","volume":"24","author":"Mac\u00e9","year":"2005","journal-title":"EMBO J."},{"key":"B9","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1124\/pr.112.005942","article-title":"Regulation of \u03bc-opioid receptors: desensitization, phosphorylation, internalization, and tolerance","volume":"65","author":"Williams","year":"2013","journal-title":"Pharmacol Rev."},{"key":"B10","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.biopsych.2019.05.023","article-title":"Neurobiology of opioid addiction: opponent process, hyperkatifeia and negative reinforcement","volume":"87","author":"Koob","year":"2019","journal-title":"Biol Psychiatry."},{"key":"B11","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jbspin.2007.09.010","article-title":"Pathogenesis of fibromyalgia \u2013 a review","volume":"75","author":"Ablin","year":"2008","journal-title":"Joint Bone Spine."},{"key":"B12","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s12016-015-8509-4","article-title":"Fibromyalgia: a critical and comprehensive review","volume":"49","author":"Borchers","year":"2015","journal-title":"Clin Rev Allergy Immunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1001\/jama.2014.3266","article-title":"Fibromyalgia","volume":"311","author":"Clauw","year":"2014","journal-title":"JAMA."},{"key":"B14","doi-asserted-by":"publisher","first-page":"169","DOI":"10.12659\/MSMBR.915962","article-title":"Fibromyalgia and its new lessons for neuropsychiatry","volume":"25","author":"Duque","year":"2019","journal-title":"Med Sci Monit Basic Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"15022","DOI":"10.1038\/nrdp.2015.22","article-title":"Fibromyalgia","volume":"1","author":"H\u00e4user","year":"2015","journal-title":"Nat Rev Dis Primer."},{"key":"B16","doi-asserted-by":"publisher","first-page":"g1224","DOI":"10.1136\/bmj.g1224","article-title":"Fibromyalgia","volume":"348","author":"Rahman","year":"2014","journal-title":"BMJ."},{"key":"B17","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.psym.2011.11.006","article-title":"Is fibromyalgia an endocrine\/endorphin deficit disorder? Is low dose naltrexone a new treatment option?","volume":"53","author":"Ramanathan","year":"2012","journal-title":"Psychosomatics."},{"key":"B18","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/art.1780330203","article-title":"The American college of rheumatology 1990 criteria for the classification of fibromyalgia","volume":"33","author":"Wolfe","year":"1990","journal-title":"Arthritis Rheum."},{"key":"B19","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.mehy.2008.06.048","article-title":"Low-dose naltrexone for disease prevention and quality of life","volume":"72","author":"Brown","year":"2009","journal-title":"Med Hypotheses."},{"key":"B20","first-page":"209","article-title":"Fibromyalgia, autism, and opioid addiction as natural and induced disorders of the endogenous opioid hormonal system","volume":"18","author":"Johnson","year":"2014","journal-title":"Discov Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/0304-3959(91)90068-9","article-title":"No evidence for endorphin deficiency in fibromyalgia following investigation of cerebrospinal fluid (CSF) dynorphin A and Met-enkephalin-Arg6-Phe7","volume":"46","author":"Vaer\u00f8y","year":"1991","journal-title":"Pain."},{"key":"B22","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/1471-2474-5-48","article-title":"Cerebrospinal fluid levels of opioid peptides in fibromyalgia and chronic low back pain","volume":"5","author":"Baraniuk","year":"2004","journal-title":"BMC Musculoskelet Disord."},{"key":"B23","doi-asserted-by":"publisher","first-page":"10000","DOI":"10.1523\/JNEUROSCI.2849-07.2007","article-title":"Decreased central \u03bc-opioid receptor availability in fibromyalgia","volume":"27","author":"Harris","year":"2007","journal-title":"J Neurosci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1471-2210-6-3","article-title":"Pharmacological profiles of opioid ligands at Kappa opioid receptors","volume":"6","author":"Gharagozlou","year":"2006","journal-title":"BMC Pharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/j.1460-9568.2008.06321.x","article-title":"Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4)","volume":"28","author":"Hutchinson","year":"2008","journal-title":"Eur J Neurosci."},{"key":"B26","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3109\/00207459208994788","article-title":"Enkephalins, brain and immunity: modulation of immune responses by methionine-enkephalin injected into the cerebral cavity","volume":"67","author":"Jankovi\u0107","year":"1992","journal-title":"Int J Neurosci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1242\/jeb.073411","article-title":"Immune\u2013neural connections: how the immune system's response to infectious agents influences behavior","volume":"216","author":"McCusker","year":"2013","journal-title":"J Exp Biol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.bcp.2015.06.016","article-title":"Duration of opioid receptor blockade determines biotherapeutic response","volume":"97","author":"McLaughlin","year":"2015","journal-title":"Biochem Pharmacol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.brainres.2011.01.036","article-title":"Prevention and diminished expression of experimental autoimmune encephalomyelitis by low dose naltrexone (LDN) or opioid growth factor (OGF) for an extended period: therapeutic implications for multiple sclerosis","volume":"1381","author":"Rahn","year":"2011","journal-title":"Brain Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S0196-9781(00)00233-3","article-title":"Nociceptin\/orphanin FQ and neurotransmitter release in the central nervous system","volume":"21","author":"Schlicker","year":"2000","journal-title":"Peptides."},{"key":"B31","doi-asserted-by":"publisher","first-page":"5038","DOI":"10.1021\/acs.jmedchem.5b00426","article-title":"Structure\u2013activity relationships of (+)-naltrexone-inspired toll-like receptor 4 (TLR4) antagonists","volume":"58","author":"Selfridge","year":"2015","journal-title":"J Med Chem."},{"key":"B32","first-page":"345","article-title":"Study on structural insight of the analysis of negative effects of opioids analgesics in naltrexone with TLR4 Mutations","volume":"32","author":"Tariq","year":"2019","journal-title":"Pak J Pharm Sci."},{"key":"B33","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1021\/acschemneuro.8b00488","article-title":"Ethanol and naltrexone have distinct effects on the lateral nano-organization of mu and kappa opioid receptors in the plasma membrane","volume":"10","author":"Tobin","year":"2018","journal-title":"ACS Chem Neurosci."},{"key":"B34","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3390\/medsci6040082","article-title":"Low-dose naltrexone (LDN)\u2014review of therapeutic utilization","volume":"6","author":"Toljan","year":"2018","journal-title":"Med Sci."},{"key":"B35","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1111\/bph.13394","article-title":"Pharmacological characterization of the opioid inactive isomers (+)-naltrexone and (+)-naloxone as antagonists of toll-like receptor 4","volume":"173","author":"Wang","year":"2016","journal-title":"Br J Pharmacol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/sj.npp.1301440","article-title":"Differences in \u03b4- and \u03bc-opioid receptor blockade measured by positron emission tomography in naltrexone-treated recently abstinent alcohol-dependent subjects","volume":"33","author":"Weerts","year":"2008","journal-title":"Neuropsychopharmacology."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1177\/1535370218817746","article-title":"Intermittent blockade of OGFr and treatment of autoimmune disorders","volume":"243","author":"Zagon","year":"2018","journal-title":"Exp Biol Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.bcp.2012.05.018","article-title":"The opioid growth factor\u2013opioid growth factor receptor axis: Homeostatic regulator of cell proliferation and its implications for health and disease","volume":"84","author":"McLaughlin","year":"2012","journal-title":"Biochem Pharmacol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1097\/00002060-198902000-00003","article-title":"Normative model for cold pressor test","volume":"68","author":"Walsh","year":"1989","journal-title":"Am J Phys Med Rehabil."},{"key":"B40","doi-asserted-by":"publisher","first-page":"E126","DOI":"10.1111\/papr.12142","article-title":"Two-week test\u2013retest stability of the cold pressor task procedure at two different temperatures as a measure of pain threshold and tolerance","volume":"14","author":"Koenig","year":"2014","journal-title":"Pain Pract."},{"key":"B41","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1111\/1745-8315.12289","article-title":"New developments in transference focused psychotherapy","volume":"97","author":"Kernberg","year":"2016","journal-title":"Int J Psychoanal."},{"key":"B42","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1080\/15289168.2015.1006008","article-title":"Transference-focused psychotherapy for borderline adolescents: a neurobiologically informed psychodynamic psychotherapy","volume":"14","author":"Normandin","year":"2015","journal-title":"J Infant Child Adolesc Psychother."},{"key":"B43","first-page":"197","article-title":"Clinical utility of the cold pressor test: evaluation of pain patients, treatment of opioid-induced hyperalgesia and fibromyalgia with low dose naltrexone","volume":"26","author":"Oaks","year":"2018","journal-title":"Discov Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/15294145.2013.10799827","article-title":"Outpatient detoxification completion and one-month outcomes for opioid dependence: a preliminary study of a neuropsychoanalytic treatment in pain patients and addicted patients","volume":"15","author":"Johnson","year":"2013","journal-title":"Neuropsychoanalysis."},{"key":"B45","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12865-015-0093-0","article-title":"Endogenous opioid inhibition of proliferation of T and B cell subpopulations in response to immunization for experimental autoimmune encephalomyelitis","volume":"16","author":"McLaughlin","year":"2015","journal-title":"BMC Immunol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.brainres.2009.11.026","article-title":"Opioid growth factor suppresses expression of experimental autoimmune encephalomyelitis","volume":"1310","author":"Zagon","year":"2010","journal-title":"Brain Res."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.3181\/0906-RM-189","article-title":"Endogenous opioids regulate expression of experimental autoimmune encephalomyelitis: a new paradigm for the treatment of multiple sclerosis","volume":"234","author":"Zagon","year":"2009","journal-title":"Exp Biol Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jneuroim.2015.02.002","article-title":"Evidence of different mediators of central inflammation in dysfunctional and inflammatory pain \u2014 Interleukin-8 in fibromyalgia and interleukin-1 \u03b2 in rheumatoid arthritis","volume":"280","author":"Kosek","year":"2015","journal-title":"J Neuroimmunol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.bbi.2018.09.018","article-title":"Brain glial activation in fibromyalgia \u2013 a multi-site positron emission tomography investigation","volume":"75","author":"Albrecht","year":"2018","journal-title":"Brain Behav Immun."},{"key":"B50","doi-asserted-by":"publisher","first-page":"515","DOI":"10.2147\/JPR.S128508","article-title":"Evidence of both systemic inflammation and neuroinflammation in fibromyalgia patients, as assessed by a multiplex protein panel applied to the cerebrospinal fluid and to plasma","volume":"10","author":"B\u00e4ckryd","year":"2017","journal-title":"J Pain Res."},{"key":"B51","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1111\/j.1526-4637.2009.00613.x","article-title":"Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study","volume":"10","author":"Younger","year":"2009","journal-title":"Pain Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.jpain.2010.10.003","article-title":"Gray matter volumes of pain-related brain areas are decreased in fibromyalgia syndrome","volume":"12","author":"Robinson","year":"2011","journal-title":"J Pain."},{"key":"B53","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1097\/j.pain.0000000000001167","article-title":"Lateralized kappa opioid receptor signaling from the amygdala central nucleus promotes stress-induced functional pain","volume":"159","author":"Nation","year":"2018","journal-title":"Pain."},{"key":"B54","first-page":"364","article-title":"Functional imaging of pain in patients with primary fibromyalgia","volume":"31","author":"Cook","year":"2004","journal-title":"J Rheumatol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.pain.2009.03.017","article-title":"No consistent difference in gray matter volume between individuals with fibromyalgia and age-matched healthy subjects when controlling for affective disorder","volume":"143","author":"Hsu","year":"2009","journal-title":"Pain."},{"key":"B56","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1093\/brain\/awq138","article-title":"Alterations in brain structure and functional connectivity in prescription opioid-dependent patients","volume":"133","author":"Upadhyay","year":"2010","journal-title":"Brain."},{"key":"B57","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.brainres.2009.09.074","article-title":"Dynorphin, stress, and depression","volume":"1314","author":"Knoll","year":"2010","journal-title":"Brain Res."},{"key":"B58","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.tins.2012.11.002","article-title":"Opioid receptors: distinct roles in mood disorders","volume":"36","author":"Lutz","year":"2013","journal-title":"Trends Neurosci."},{"key":"B59","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1097\/j.pain.0000000000001458","article-title":"Kappa opioid signaling in the central nucleus of the amygdala promotes disinhibition and aversiveness of chronic neuropathic pain","volume":"160","author":"Navratilova","year":"2019","journal-title":"Pain."},{"key":"B60","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1037\/h0036128","article-title":"An opponent-process theory of motivation: I. Temporal dynamics of affect","volume":"81","author":"Solomon","year":"1974","journal-title":"Psychol Rev."},{"key":"B61","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.tips.2016.08.002","article-title":"Allostatic mechanisms of opioid tolerance beyond desensitization and downregulation","volume":"37","author":"Cahill","year":"2016","journal-title":"Trends Pharmacol Sci."},{"key":"B62","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jsat.2014.03.004","article-title":"Reasons for opioid use among patients with dependence on prescription opioids: the role of chronic pain","volume":"47","author":"Weiss","year":"2014","journal-title":"J Subst Abuse Treat."},{"key":"B63","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.drugalcdep.2013.01.007","article-title":"Heroin use and heroin use risk behaviors among nonmedical users of prescription opioid pain relievers \u2013 United States, 2002\u20132004 and 2008\u20132010","volume":"132","author":"Jones","year":"2013","journal-title":"Drug Alcohol Depend."},{"key":"B64","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1097\/01.ajp.0000161526.25374.e5","article-title":"Direct comparison of placebo effects on clinical and experimental pain","volume":"22","author":"Charron","year":"2006","journal-title":"Clin J Pain."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.3389\/fpsyg.2018.01198","article-title":"Failure to find a conditioned placebo analgesic response","volume":"9","author":"Flaten","year":"2018","journal-title":"Front Psychol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.neuron.2008.06.030","article-title":"New insights into the placebo and nocebo responses","volume":"59","author":"Enck","year":"2008","journal-title":"Neuron."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1126\/science.1060937","article-title":"Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease","volume":"293","author":"de la Fuente-Fern\u00e1ndez","year":"2001","journal-title":"Science."},{"key":"B68","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.neuron.2007.06.028","article-title":"Individual differences in reward responding explain placebo-induced expectations and effects","volume":"55","author":"Scott","year":"2007","journal-title":"Neuron."},{"key":"B69","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1001\/archgenpsychiatry.2007.34","article-title":"Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses","volume":"65","author":"Scott","year":"2008","journal-title":"Arch Gen Psychiat."},{"key":"B70","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1093\/pm\/pnaa001","article-title":"Low-dose naltrexone for the treatment of fibromyalgia: investigation of dose\u2013response relationships","volume":"21","author":"Bruun-Plesner","year":"2020","journal-title":"Pain Med."},{"key":"B71","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1097\/00005053-196906000-00004","article-title":"Changes in personality and subjective experience associated with the chronic administration and withdrawal of opiates","volume":"148","author":"Haertzen","year":"1969","journal-title":"J Nerv Ment Dis."},{"key":"B72","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s00213-009-1472-0","article-title":"Abnormal pain response in pain-sensitive opiate addicts after prolonged abstinence predicts increased drug craving","volume":"204","author":"Ren","year":"2009","journal-title":"Psychopharmacology (Berl)."},{"key":"B73","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1111\/ajad.12605","article-title":"Ameliorative response to detoxification, psychotherapy, and medical management in patients maintained on opioids for pain","volume":"26","author":"Belkin","year":"2017","journal-title":"Am J Addict."}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2021.593842\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,25]],"date-time":"2021-04-25T07:48:24Z","timestamp":1619336904000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2021.593842\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,16]]},"references-count":73,"alternative-id":["10.3389\/fpsyt.2021.593842"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2021.593842","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,16]]},"article-number":"593842"}}